Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 18/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.39 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4035646 | 0.91 | TGFBR1 (0.48) | TGFBR1MAPK14MTORTGFBR2MAP3K20 | |
| SCHEMBL4035268 | 0.84 | TGFBR1 (0.60) | TGFBR1MAPK14MTOR | |
| SCHEMBL4030670 | 0.83 | TGFBR1 (0.41) | TGFBR1MAPK14MTORTGFBR2MAP3K20 | |
| SCHEMBL4031539 | 0.82 | TGFBR1 (0.44) | TGFBR1MAPK14MTORTGFBR2MAP3K20 | |
| SCHEMBL4033122 | 0.80 | TGFBR1 (0.58) | TGFBR1MAPK14MTOR | |
| SCHEMBL4033292 | 0.80 | TGFBR1 (0.53) | TGFBR1MAPK14MTORTGFBR2 | |
| SCHEMBL5655965 | 0.77 | TGFBR1 (0.55) | TGFBR1MAPK14MTORTGFBR2MAP3K20 | |
| SCHEMBL4860142 | 0.77 | TGFBR1 (0.38) | TGFBR1MAPK14MTORTGFBR2MAP3K20 | |
| SCHEMBL4488213 | 0.76 | TGFBR1 (0.51) | TGFBR1MAPK14MTORTGFBR2MAP3K20 | |
| SCHEMBL4031582 | 0.76 | TGFBR1 (0.44) | TGFBR1MAPK14MTORTGFBR2MAP3K20 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7273936-B2 | Oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC. (US) | 2007-09-25 | — | — | US | claimed |
| EP-1542994-B1 | NOVEL OXAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITOR | PFIZER PROD INC (US) | 2009-04-29 | — | — | EP | disclosed |
| US-7273936-B2 | Oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC. (US) | 2007-09-25 | — | — | US | disclosed |
| EP-1542994-A1 | NOVEL TRIAZOLE AND OXAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITOR | Pfizer Products Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040110797-A1 | Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC | 2004-06-10 | — | — | US | disclosed |
| WO-2004026863-A1 | NOVEL OXAZOLE AND THIAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110797-A1 | Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors | TGFBR1, TGFBR2, SMAD3 | TGFBR1 1/4885MAPK14 319/4885MTOR 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.